
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.

Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.
إسطنبول، تركيا – (ARAB NEWSWIRE) — بدأت شركة ANT Systems الزراعية المتخصصة في تكنولوجيا النانو…
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…
Mehmet Oz, a physician and TV personality, takes office as HHS lays off thousands of staffers and Republicans float potential…
Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with…
Just two acquisitions in the first quarter, that of Intra-Cellular Therapies and IDRx, crossed the $1 billion mark, a notable…
Indoximod (1-methyl-D-tryptophan) In Chapter 2 of our 2017 book-length report, Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes…
Sign in to your account